David R. Clemmons

40.4k total citations · 8 hit papers
344 papers, 30.2k citations indexed

About

David R. Clemmons is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cancer Research. According to data from OpenAlex, David R. Clemmons has authored 344 papers receiving a total of 30.2k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Endocrinology, Diabetes and Metabolism, 175 papers in Molecular Biology and 57 papers in Cancer Research. Recurrent topics in David R. Clemmons's work include Growth Hormone and Insulin-like Growth Factors (234 papers), Metabolism, Diabetes, and Cancer (95 papers) and Pituitary Gland Disorders and Treatments (46 papers). David R. Clemmons is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (234 papers), Metabolism, Diabetes, and Cancer (95 papers) and Pituitary Gland Disorders and Treatments (46 papers). David R. Clemmons collaborates with scholars based in United States, Russia and United Kingdom. David R. Clemmons's co-authors include John I. Jones, Louis E. Underwood, Walker H. Busby, Judson J. Van Wyk, A Gockerman, Laura A. Maile, Wendie S. Cohick, ROBERT G. ELGIN, Cecilia Camacho‐Hübner and David K. Snyder and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David R. Clemmons

330 papers receiving 29.3k citations

Hit Papers

Insulin-Like Growth Factors and Their Binding Proteins: B... 1987 2026 2000 2013 1995 1998 2011 1987 1993 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
    1995 3.9k citations John I. Jones, David R. Clemmons profile →
  2. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review
    1998 665 citations David R. Clemmons, Raymond L. Hintz et al. The Journal of Clinical Endocrinology & Metabolism profile →
  3. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
    2011 639 citations Mark E. Molitch, David R. Clemmons et al. The Journal of Clinical Endocrinology & Metabolism profile →
  4. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.
    1987 590 citations Walker H. Busby, David R. Clemmons et al. profile →
  5. The Insulin-Like Growth Factors
    1993 549 citations David R. Clemmons et al. profile →
  6. Guidelines for Acromegaly Management: An Update
    2009 549 citations Шломо Мелмед, Annamaria Colao et al. The Journal of Clinical Endocrinology & Metabolism profile →
  7. Assessment of Growth Parameters and Life Span of GHR/BP Gene-Disrupted Mice1
    2000 501 citations David R. Clemmons et al. Endocrinology profile →
  8. A Consensus Statement on acromegaly therapeutic outcomes
    2018 389 citations Шломо Мелмед, Marcello D. Bronstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David R. Clemmons United States 87 20.4k 12.1k 4.6k 4.4k 4.1k 344 30.2k
Robert C. Baxter Australia 78 16.0k 0.8× 10.4k 0.9× 3.3k 0.7× 4.4k 1.0× 2.3k 0.6× 397 22.9k
Ron G. Rosenfeld United States 83 15.0k 0.7× 9.4k 0.8× 6.5k 1.4× 2.6k 0.6× 1.7k 0.4× 448 23.3k
Pinchas Cohen United States 79 8.6k 0.4× 10.1k 0.8× 2.8k 0.6× 3.6k 0.8× 5.8k 1.4× 318 22.5k
Richard P. Lifton United States 92 9.7k 0.5× 20.6k 1.7× 5.6k 1.2× 1.4k 0.3× 1.8k 0.4× 276 35.1k
John J. Kopchick United States 70 9.3k 0.5× 6.3k 0.5× 3.0k 0.7× 1.9k 0.4× 5.7k 1.4× 458 18.6k
Charles T. Roberts United States 67 8.4k 0.4× 8.4k 0.7× 2.6k 0.6× 2.3k 0.5× 1.8k 0.4× 264 16.9k
Derek LeRoith United States 64 9.3k 0.5× 8.0k 0.7× 2.4k 0.5× 2.4k 0.5× 1.7k 0.4× 181 16.1k
Andrew R. Hoffman United States 76 6.0k 0.3× 7.5k 0.6× 3.1k 0.7× 2.0k 0.5× 3.8k 0.9× 343 18.3k
Subburaman Mohan United States 72 7.8k 0.4× 8.7k 0.7× 3.6k 0.8× 2.3k 0.5× 1.6k 0.4× 366 18.0k
Шломо Мелмед United States 94 23.1k 1.1× 6.7k 0.6× 2.1k 0.5× 2.9k 0.7× 1.3k 0.3× 477 31.2k

Countries citing papers authored by David R. Clemmons

Since Specialization
Citations

This map shows the geographic impact of David R. Clemmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Clemmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Clemmons more than expected).

Fields of papers citing papers by David R. Clemmons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Clemmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Clemmons. The network helps show where David R. Clemmons may publish in the future.

Co-authorship network of co-authors of David R. Clemmons

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Clemmons. A scholar is included among the top collaborators of David R. Clemmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Clemmons. David R. Clemmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wass, John, Anne Klibanski, Шломо Мелмед, et al.. (2025). A Consensus Statement on acromegaly therapeutic outcomes. UNC Libraries.
2.
Biller, Beverly M. K., Christian J. Strasburger, Martin Bidlingmaier, et al.. (2025). OR12-07 Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension. Journal of the Endocrine Society. 9(Supplement_1).
3.
Gadelha, Mônica R., Christian J. Strasburger, Martin Bidlingmaier, et al.. (2024). Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of Clinical Endocrinology & Metabolism. 110(1). 228–237. 12 indexed citations
4.
Xi, Gang, Christine Wai, & David R. Clemmons. (2019). Inhibition of Aberrant IGF-I Signaling in Diabetic Male Rat Retina Prevents and Reverses Changes of Diabetic Retinopathy. Journal of Diabetes Research. 2019. 1–14. 7 indexed citations
5.
Clemmons, David R., Sam S. Miller, & Jean‐Claude Mamputu. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS ONE. 12(6). e0179538–e0179538. 14 indexed citations
6.
7.
Kawai, Masanobu, Anne Breggia, Victoria DeMambro, et al.. (2011). The Heparin-binding Domain of IGFBP-2 Has Insulin-like Growth Factor Binding-independent Biologic Activity in the Growing Skeleton. Journal of Biological Chemistry. 286(16). 14670–14680. 50 indexed citations
8.
Clemmons, David R. & David E. Bruns. (2011). In Reply. Clinical Chemistry. 57(10). 1463–1464. 2 indexed citations
9.
Fazeli, Pouneh K., Elizabeth A. Lawson, Rajani Prabhakaran, et al.. (2010). Effects of Recombinant Human Growth Hormone in Anorexia Nervosa: A Randomized, Placebo-Controlled Study. The Journal of Clinical Endocrinology & Metabolism. 95(11). 4889–4897. 80 indexed citations
10.
Мелмед, Шломо, Annamaria Colao, Ariel L. Barkan, et al.. (2009). Guidelines for Acromegaly Management: An Update. The Journal of Clinical Endocrinology & Metabolism. 94(5). 1509–1517. 549 indexed citations breakdown →
11.
Zheng, Bo & David R. Clemmons. (2003). Methods for Preparing Extracellular Matrix and Quantifying Insulin-like Growth Factor-Binding Protein Binding to the ECM. Humana Press eBooks. 139. 221–230. 4 indexed citations
12.
Maile, Laura A., et al.. (2003). The Association between Integrin-associated Protein and SHPS-1 Regulates Insulin-like Growth Factor-I Receptor Signaling in Vascular Smooth Muscle Cells. Molecular Biology of the Cell. 14(9). 3519–3528. 46 indexed citations
13.
Nam, Taek‐Jeong, et al.. (2002). Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions. Endocrinology. 143(1). 30–36. 41 indexed citations
14.
Klibanski, Anne, Ken K. Y. Ho, Pamela U. Freda, et al.. (2001). State-of-the-Art Strategies for the Diagnosis and Management of Acromegaly. The Endocrinologist. 11(3). 223–232. 4 indexed citations
15.
16.
Clemmons, David R., Walker H. Busby, T Arai, et al.. (1995). Role of insulin-like growth factor binding proteins in the control of IGF actions. PubMed. 6(2-4). 357–366. 65 indexed citations
17.
Camacho‐Hübner, Cecilia, David R. Clemmons, & A. Joseph D’Ercole. (1991). Regulation of Insulin-Like Growth Factor (IGF) Binding Proteins in Transgenic Mice with Altered Expression of Growth Hormone and IGF-I. Endocrinology. 129(3). 1201–1206. 64 indexed citations
18.
Baumann, G, et al.. (1988). Growth hormone binding protein in human plasma downregulation by prolonged fasting in lean but not obese subjects. Clinical research. 36(3). 477. 11 indexed citations
19.
Herman, B., et al.. (1987). Platelet‐derived growth factor‐induced alterations in vinculin distribution in porcine vascular smooth muscle cells. Cell Motility and the Cytoskeleton. 8(2). 91–105. 34 indexed citations
20.
Wyk, Judson J. Van, L E Underwood, Joel B. Baseman, et al.. (1975). Explorations of the Insulinlike and Growth-Promoting Properties of Somatomedin by Membrane Receptor Assays. PubMed. 8. 127–150. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert C. Baxter Breakdown of academic impact, for papers by Ron G. Rosenfeld Breakdown of academic impact, for papers by Pinchas Cohen Breakdown of academic impact, for papers by Richard P. Lifton Breakdown of academic impact, for papers by John J. Kopchick Breakdown of academic impact, for papers by Charles T. Roberts Breakdown of academic impact, for papers by Derek LeRoith Breakdown of academic impact, for papers by Andrew R. Hoffman Breakdown of academic impact, for papers by Subburaman Mohan Breakdown of academic impact, for papers by Шломо Мелмед
Rankless by CCL
2026